跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
陳 傳霖
副教授
生物醫學影像暨放射科學系
電話
(02)2826-7062, (02)2826-7000 #65591
電子郵件
clchen2
ym.edu
tw
h-index
h10-index
h5-index
584
引文
15
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
179
引文
9
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
68
引文
5
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2004
2024
每年研究成果
概覽
指紋
網路
研究成果
(38)
類似的個人檔案
(6)
指紋
查看啟用 Chuan-Lin Chen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Tumor
53%
Mouse Model
51%
Malignant Melanoma
37%
Photothermal Therapy
33%
Melanin
32%
Tumor-bearing Mice
32%
Biodistribution
29%
Iodine-131 (131I)
29%
Biodistribution Studies
27%
Melanoma
27%
Gold Nanostars
26%
Single-photon Emission Computed Tomography (SPECT)
25%
Photothermal
24%
Technetium-99m
23%
Lutetium-177 (177Lu)
23%
Muscle Ratio
20%
Theranostic Agent
20%
Radiochemical Yield
19%
Synthetic Evaluation
17%
Biological Evaluation
17%
Aryl Halides
17%
Suzuki-Miyaura Coupling
17%
Asialoglycoprotein Receptor (ASGPR)
17%
Hepatic Fibrosis
17%
Positron Emission Tomography Scanner
17%
Efficient Catalyst
17%
Arylboronic Acids
17%
Thymidine Kinase
17%
Upconversion Nanoparticles
17%
Targeted Imaging
17%
Upconversion
17%
Radiotracer
16%
Radiochemical Purity
15%
Cellular Uptake
15%
Radioactivity
15%
Lipophilic
14%
Tumor Accumulation
13%
Tumor Retention
13%
Liver
13%
Therapeutic Efficacy
13%
Palladium Nanoparticles (PdNPs)
13%
Biological Characteristics
13%
Aerobic Conditions
13%
Nanoformulation
13%
Nicotinamide
12%
Benzamide
12%
Sorafenib
11%
Picolinamide
11%
Tumor Mouse Model
11%
Amino
11%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Mouse Model
58%
Melanoma
43%
Biodistribution
38%
Malignant Neoplasm
36%
Fluorine 18
35%
Iodine-131
28%
Photothermal Therapy
25%
Pentetic Acid
24%
Technetium 99m
23%
Melanin
22%
Polyethylene Terephthalate
21%
Asialoglycoprotein Receptor
17%
Gold Nanoparticle
17%
Liver Fibrosis
17%
Thymidine Kinase
17%
Nanoparticle
17%
Colorectal Carcinoma
17%
Lutetium 177
16%
Indium 111
16%
Sorafenib
16%
Liver Cell Carcinoma
13%
Combination Therapy
12%
Dosimetry
12%
Galactose
10%
Iodine-123
10%
Connective Tissue Cancer
10%
Tracer
10%
Benzamide Derivative
9%
Benzamide
9%
Echo Contrast Medium
8%
Colon Carcinoma
8%
Chitosan
8%
Benzeneboronic Acid
8%
Palladium Complex
8%
Hyperthermia
8%
Human Serum Albumin
8%
Atezolizumab
8%
Tetraxetan
8%
Fiacitabine
8%
Graphene Oxide
8%
Inducible Nitric Oxide Synthase
8%
Red Fluorescent Protein
8%
Photodynamic Therapy
8%
Quinazoline
8%
Doxorubicin
8%
Ascites Tumor
8%
Tumor Model
8%
Immunotherapy
8%
Blood-Brain Barrier
8%
Medicine and Dentistry
Neoplasm
51%
Melanoma
35%
Iodine 131
29%
Positron Emission Tomography
26%
Melanin
22%
Biodistribution
19%
Malignant Neoplasm
17%
Fluorine-18
17%
Single-Photon Emission Computed Tomography
17%
Dosimetry
14%
Contrast Medium
11%
Iodine 123
10%
Polyethylene Terephthalate
9%
In Vitro
9%
Upconversion Nanoparticle
8%
Brain Cancer
8%
Diagnosis
8%
Artifact Reduction
8%
Human Alphaherpesvirus 1
8%
Breast Cancer
8%
Combination Therapy
8%
Benzothiazole
8%
Photochemotherapy
8%
Pentetic Acid
8%
Phototherapy
8%
Fiacitabine
8%
Brachytherapy
8%
Acetanilide
8%
Thymidine Kinase
8%
Nanoparticle
8%
Tumor Model
8%
Intracranial Tumor
8%
Iododeoxycytidine
8%
Head and Neck Tumor
8%
Optical Rotation
8%
Nanomaterial
8%
Gadolinium
8%
Bovine Serum Albumin
8%
Radioactive Tracer
8%
Benzamide
8%
Magnetic Resonance Imaging
7%
Technetium-99
5%
Imaging Agent
5%
Multimodal Imaging
5%
Computer Assisted Tomography
5%
Rose Bengal
5%
